Anti-angiogenesis Tyrosine kinase inhibitors (TKIs) have been proved to show promising effects on prolonging progression-free survival (PFS) for advanced chondrosarcoma after failure of standard multimodal Therapy. Methylsulfonic apatinib is one of those TKIs which specifically inhibits VEGFR-2. This study summarizes the experience of two Peking University affiliated hospitals in off-label use of apatinib in the treatment of extensively pre-treated chondrosarcoma.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Apatinib orally 500mg once daily half an hour after meal
Musculoskeletal Tumor Center of Peking University People's Hospital
Beijing, Beijing Municipality, China
Peking Univresity Shougang Hospital
Beijing, Beijing Municipality, China
progression-free survival
from initial treatment to date of recorded progression or death or last follow-up
Time frame: 6 months
overall survival
from initial treatment to death or last follow-up
Time frame: 5 years
objective response rate
CR+PR according to RECIST 1.1
Time frame: 6 months
clinical benefit rate
CR+PR+SD according to RECIST 1.1
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.